undamentalytics Newsletter
Sign in

Revvity revenue

Revvity's revenue was $2.86bn in fiscal 2025, up 3.7% on the year before. Since fiscal 2009 ($1.55bn) it has grown at a compound 3.9% a year. Over the last twelve months it was $2.91bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Jan 20102010Jan 20112011Jan 20122012Dec 20122013Dec 20132014Dec 20142015Jan 20162016Jan 20172017Dec 20172018Dec 20182019Dec 20192020Jan 20212021Jan 20222022Jan 20232023Dec 20232024Dec 20242025Dec 2025LTMJul 2026
Revenue1,5511,7041,9192,1152,1582,2372,1052,1162,2572,7782,8843,7833,8283,3122,7512,7552,8562,912
Growth on the year before—+9.9%+12.6%+10.3%+2.0%+3.7%−5.9%+0.5%+6.7%+23.1%+3.8%+31.2%+1.2%−13.5%−16.9%+0.2%+3.7%—
Gross profit6997618489639761,0059641,0131,0741,3411,3962,1102,4341,990————
Gross margin45.1%44.7%44.2%45.5%45.2%44.9%45.8%47.9%47.6%48.3%48.4%55.8%63.6%60.1%————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 28, 2025
Segments
Line of business Revenue Share YoY
Life Sciences $1.4B 50.1% ▲ 2.3%
Diagnostics $1.4B 49.9% ▲ 5.1%
Products and services
Line of business Revenue Share YoY
Products $2.4B 83.7% ▲ 2.2%
Services $466M 16.3% ▲ 11.8%
Geography
Region Revenue YoY
Total International $1.7B ▲ 4.4%
Americas $1.3B ▲ 2.7%
United States $1.1B ▲ 2.6%
Other International $1B ▲ 7.4%
Europe $825M ▲ 11.1%
Asia $775M ▼ 1.8%
China $425M ▼ 5.5%
Germany $178M ▲ 9.3%
United Kingdom $127M ▲ 12.4%

These categories overlap or exclude eliminations, so shares aren't shown.

From Revvity's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Revvity $2.91bn 4.1% 0.9%
Insulet Corporation $3.05bn 29.4% 27.7%
Globus Medical Inc $3.14bn 19.7% 42.1%
Quidelortho Corp $2.67bn -2.5% -5.4%
Enovis Corp $2.30bn 4.9% 12.2%
Teleflex Inc $2.25bn 30.7% -8.0%

Compare with peers

Head to head: PODD vs RVTYGMED vs RVTYQDEL vs RVTY

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Revvity's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Revvity.